MX2023014073A - Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos. - Google Patents

Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos.

Info

Publication number
MX2023014073A
MX2023014073A MX2023014073A MX2023014073A MX2023014073A MX 2023014073 A MX2023014073 A MX 2023014073A MX 2023014073 A MX2023014073 A MX 2023014073A MX 2023014073 A MX2023014073 A MX 2023014073A MX 2023014073 A MX2023014073 A MX 2023014073A
Authority
MX
Mexico
Prior art keywords
cell receptors
ras mutations
receptors targeting
targeting ras
tcrs
Prior art date
Application number
MX2023014073A
Other languages
English (en)
Spanish (es)
Inventor
Christopher A Klebanoff
Smita S Chandran
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2023014073A publication Critical patent/MX2023014073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
MX2023014073A 2021-05-25 2022-05-25 Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos. MX2023014073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192783P 2021-05-25 2021-05-25
PCT/US2022/030814 WO2022251283A1 (en) 2021-05-25 2022-05-25 T cell receptors targeting ras mutations and uses thereof

Publications (1)

Publication Number Publication Date
MX2023014073A true MX2023014073A (es) 2024-02-21

Family

ID=84230235

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014073A MX2023014073A (es) 2021-05-25 2022-05-25 Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos.

Country Status (11)

Country Link
US (1) US20240091361A1 (https=)
EP (1) EP4347639A4 (https=)
JP (1) JP2024520427A (https=)
KR (1) KR20240013750A (https=)
CN (1) CN117545766A (https=)
AU (1) AU2022283277A1 (https=)
BR (1) BR112023024595A2 (https=)
CA (1) CA3219923A1 (https=)
IL (1) IL308755A (https=)
MX (1) MX2023014073A (https=)
WO (1) WO2022251283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024039576A2 (en) * 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
AU2024228388A1 (en) * 2023-02-27 2025-10-02 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024339041A1 (en) * 2023-09-05 2026-04-16 Bluesphere Bio, Inc. T cell receptors targeting an npm1 neoantigen
WO2025137468A1 (en) * 2023-12-22 2025-06-26 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CA3116749A1 (en) * 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途

Also Published As

Publication number Publication date
EP4347639A1 (en) 2024-04-10
CN117545766A (zh) 2024-02-09
WO2022251283A1 (en) 2022-12-01
AU2022283277A1 (en) 2023-12-14
IL308755A (en) 2024-01-01
BR112023024595A2 (pt) 2024-02-15
EP4347639A4 (en) 2025-08-06
CA3219923A1 (en) 2022-12-01
US20240091361A1 (en) 2024-03-21
JP2024520427A (ja) 2024-05-24
AU2022283277A9 (en) 2024-01-04
KR20240013750A (ko) 2024-01-30

Similar Documents

Publication Publication Date Title
MX2023014073A (es) Receptores de linfocitos t que se dirigen a mutaciones de ras y usos de los mismos.
MX2021002575A (es) Conjugados de polipeptidos de interleucina-2 y sus usos.
MX2022007575A (es) Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos.
ZA202310395B (en) Substituted inhibitors of menin-mll and methods of use
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
ZA201905470B (en) Method for generating t cells progenitors
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
WO2017161069A8 (en) Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnostics
MX2022005389A (es) Terapia de celulas t con receptor de antigeno quimerico.
PH12022550102A1 (en) Chimeric antigen receptors with mage-a4 specificity and uses thereof
MX2022011532A (es) Dispositivo de camara celular implantable y usos de este.
MX2022014247A (es) Biomarcadores tumorales para inmunoterapia.
AU2017254665A1 (en) Compositions and methods for enhanced gene expression of pklr
MY209449A (en) Anti-cd19 therapy in patients having a limited number of nk cells
EP4656196A3 (en) T cell receptors targeting pik3ca mutations and uses thereof
MX2025012361A (es) Tecnologias dirigidas a estados celulares
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
EP4434541A3 (en) Antibodies specific to delta 1 chain of t cell receptor
EP4527947A3 (en) Predicting peptide receptor radiotherapy using a gene expression assay
WO2022015972A3 (en) Sonogenetic stimulation of cells expressing trpa1
MX2021005847A (es) Gen suicida.
WO2024039576A3 (en) T cell receptors targeting ras mutations and uses thereof
Ohashi et al. Human TUBG 2 gene is expressed as two splice variant mRNA and involved in cell growth
MX2025010440A (es) Inmunoterapia de celulas t dirigidas por zetacina, direccionada al receptor alfa 2 de il-13
EP3859844A4 (en) BASE MATERIAL FOR GAS DIFFUSION ELECTRODE AND MANUFACTURING PROCESS THEREOF, AS WELL AS SOLID POLYMER FUEL CELL